GLP-1s for Older Adults

Maybe you’re 65 or older and your doctor brought up a GLP-1 medication at your last appointment. Maybe you’re researching for a parent or a spouse. Or maybe you’ve been watching the conversation about these drugs and wondering whether the benefits — and risks — look different when you’re not 40 anymore.

They do. In both directions.

Nearly 39% of adults over 60 in the U.S. are living with obesity, and close to 29% of adults 65 and older have diabetes.[1] These are the conditions GLP-1 medications are designed to treat. And the cardiovascular and kidney protection data from the major clinical trials is just as strong — sometimes stronger — in older adults as in younger ones. These medications can be genuinely transformative for the right person over 65.

But the stakes are higher. Muscle loss, bone density, fall risk, dehydration — these aren’t abstract concerns when you’re older. They’re the difference between living independently and not. A careful approach isn’t optional here. It’s the whole strategy.

This page walks through the real benefits, the real risks, and what a thoughtful approach looks like for older adults considering or already taking a GLP-1 medication.

---

The Cardiovascular Case — And It's Strong

Let’s start with the good news, because it’s genuinely compelling.

The major cardiovascular outcomes trials didn’t just include older adults — they showed consistent benefit in that population. Heart disease is the leading killer of older adults, and it’s amplified by both obesity and diabetes. A medication that controls blood sugar, promotes weight loss, and independently protects the heart is addressing three problems with one treatment.

---

Sarcopenia: The Central Concern

Here’s where the conversation turns — and where the stakes are different from a 45-year-old taking the same medication.

Sarcopenia is the medical term for age-related muscle loss, and it’s one of the most important health concerns in aging. Muscle mass starts declining by about 3-8% per decade after age 30, and that decline accelerates after 60.[5] By the time you’re in your 70s and 80s, you may have lost a significant portion of the muscle mass you had at 40 — and with it, the strength, balance, and functional capacity that keep you independent.

Now add a GLP-1 medication. Weight loss from any method — not just GLP-1s — involves losing some lean mass along with fat. The typical ratio is about 75% fat and 25% lean tissue. That’s true for dieting, for GLP-1 medications, and for bariatric surgery. The SURMOUNT-1 trial’s subgroup analysis of adults 65 and older actually showed a slightly better ratio than younger participants.[6] So GLP-1 medications aren’t uniquely bad for muscle. They’re about the same as every other form of weight loss.

The problem isn’t the ratio. The problem is the starting point.

When you’re 35 and you lose 25% of your weight loss as lean mass, you probably have plenty of muscle reserve to absorb that. When you’re 72 and you’ve already lost decades of muscle to normal aging, that same 25% lean mass loss can push you below critical thresholds — the thresholds where you can’t get up from a chair without help, where a stumble becomes a hip fracture, where independence starts slipping away.

This isn’t a reason to avoid GLP-1s. It’s a reason to take muscle preservation seriously — more seriously than a younger person might need to.

---

Protecting Muscle: Protein and Resistance Training

Two things protect muscle during weight loss, and neither one alone is enough. You need both.

---

Fall Risk: The Dehydration Cascade

Falls are the leading cause of injury death in adults over 65. Anything that increases fall risk in this population deserves attention — and GLP-1 medications can contribute through a specific pathway that doesn’t get talked about enough.

1. Suppressed thirst signals — GLP-1 medications can cause hypodipsia; older adults already have decreased thirst perception. Double hit on fluid intake.
2. Dehydration sets in — Less drinking plus potential nausea/vomiting in early treatment weeks accelerates fluid losses.
3. Blood pressure drops — Orthostatic hypotension (dizziness when standing) develops. In a younger person, a momentary head rush. In a 78-year-old, a fall.
4. Fall → fracture → loss of independence — A hip fracture in an older adult can mean hospital, rehab, and permanent functional decline.

The FDA has issued warnings about kidney injury with GLP-1 medications, and dehydration is a major driver of that risk. The solution isn’t complicated — deliberate, scheduled fluid intake rather than relying on thirst — but it requires awareness that the problem exists.

---

Bone Density: What the Data Shows

This is an area where the research is still developing, and the findings need context.

DEXA scans — the imaging studies that measure bone mineral density — have shown some decline in people taking GLP-1 medications. One study presented at the 2025 Endocrine Society meeting found lumbar spine density decreased by about 1.6% and hip density by about 2.8% in GLP-1 users. The same study found a 13% rate of new fractures in the GLP-1 group, and tirzepatide showed a 44% higher risk of osteoporosis or fracture compared to other GLP-1 medications.[7]

Those numbers sound alarming. Here’s the context.

First, weight loss from any method reduces bone density. When you carry less weight, your bones are under less mechanical stress, and they remodel accordingly. This happens with dieting, with exercise programs, and with bariatric surgery — which carries a 68% increased fracture risk, significantly higher than what’s been seen with GLP-1 medications. Second, the bone density changes with GLP-1s are modest compared to the fracture risk from conditions that GLP-1s improve — like uncontrolled diabetes and obesity-related immobility.

That said, modest isn’t zero. For someone who already has osteoporosis or osteopenia — reduced bone density that hasn’t yet reached osteoporosis levels — even a small additional decline matters.

Weight-bearing exercise, adequate calcium, and vitamin D supplementation are standard recommendations for bone health in older adults. They become even more important during GLP-1 treatment. A baseline DEXA scan before starting treatment, and periodic monitoring afterward, gives providers real data to work with rather than guessing.

---

Dose Considerations: Start Low, Go Slow

Every GLP-1 prescribing guide includes a dose escalation schedule — starting at a low dose and gradually increasing to the target. For older adults, that schedule often needs to be stretched further. The phrase in geriatric medicine is “start low, go slow,” and it applies here.

---

The Obesity Paradox in Older Adults

Here’s something that makes the conversation about weight loss in older adults genuinely more complicated: there’s a well-documented phenomenon called the “obesity paradox.”

Multiple studies — 18 out of 24 in one systematic review — have found that older adults with BMIs in the 25-30 range (technically “overweight”) actually have lower mortality than those at a “normal” BMI. Carrying some extra weight in older age appears to provide a buffer during illness, surgery, or periods of reduced eating. It’s not that obesity is healthy — a BMI over 35 still carries clear risks — but the relationship between weight and health outcomes becomes less straightforward after 65.

This matters because it means aggressive weight loss targets designed for 50-year-olds may not be appropriate for 75-year-olds. The 2025 AACE obesity consensus statement reflects this nuance: for older adults, the focus should be on functional improvement and complication reduction, not hitting specific weight-loss percentages.[8] Can the person walk further? Have their blood sugars improved? Is their blood pressure better controlled? Are their knees hurting less? Those functional outcomes matter more than the number on the scale.

A provider who’s prescribing a GLP-1 to a 72-year-old with the same weight-loss target they’d set for a 48-year-old isn’t accounting for this complexity. The goal isn’t maximum weight loss. The goal is maximum quality of life.

---

Cognitive Research: Promising but Not Proven

You may have seen headlines about GLP-1 medications and brain health. Here’s where that stands, honestly.

The ELAD trial tested liraglutide in people with early Alzheimer’s disease. The primary endpoint — the main thing the study was designed to measure — was missed. But secondary analyses found 18% less cognitive decline and 50% less brain volume loss in the liraglutide group compared to placebo. Those are intriguing numbers, and they generated real excitement in the neurology community.

Then came EVOKE and EVOKE+, two larger trials testing oral semaglutide specifically for early Alzheimer’s. Both failed to meet their primary endpoints. The cognitive protection that looked promising in smaller studies didn’t hold up in bigger, more rigorous ones.

Real-world data — studies looking at large groups of people already taking GLP-1 medications — has been suggestive. People on GLP-1s appear to develop dementia at lower rates. But real-world data can’t prove causation. People who are prescribed GLP-1s may be healthier overall, more engaged with their healthcare, or different from non-users in ways that separately explain lower dementia rates.

The bottom line: there’s biological plausibility for GLP-1 medications having brain-protective effects. The early data was encouraging. The larger trials haven’t confirmed it. This is an active area of research, not a selling point for prescribing GLP-1 medications to older adults. If cognitive protection turns out to be real, that’s a future bonus — not a current reason.

---

Medicare Coverage: The Current Landscape

For many older adults, the question isn’t whether a GLP-1 would help — it’s whether they can afford one.

Here’s where things stand: Medicare Part D covers GLP-1 medications prescribed for Type 2 diabetes. It also covers them for cardiovascular risk reduction — an indication that opened up after the SELECT trial results — and for sleep apnea (Zepbound’s indication). What Medicare does not cover is GLP-1 medications prescribed purely for weight management.

That coverage gap is a big deal. Only about 9% of adults 65 and older currently use GLP-1 medications, compared to 22% of those aged 50-64. The drop-off tracks almost exactly with the Medicare eligibility threshold.

Things are shifting, though. CMS has announced the BALANCE Model, a Medicare demonstration project starting in 2027 that would cover anti-obesity medications including GLP-1s. And in late 2025, the Trump administration announced a $50-per-month demonstration program for eligible Medicare beneficiaries to access these medications.

For now, the practical reality is that older adults on Medicare who don’t have diabetes, established cardiovascular disease, or sleep apnea face significant out-of-pocket costs for GLP-1 medications — often $800-1,000+ per month at list price. Manufacturer savings cards typically can’t be used with government insurance. This is a barrier that affects the population most likely to benefit from these medications, and it’s a problem without a clean solution yet.

---

The Bottom Line

GLP-1 medications can be genuinely life-changing for older adults. The cardiovascular protection, kidney benefits, blood sugar control, and quality-of-life improvements are real, well-studied, and consistent in the 65+ population. This isn’t a case where the research was done on 40-year-olds and we’re guessing about how it applies to older people. The data is there.

But the approach needs to be different. Slower dose escalation. Proactive muscle preservation with protein and resistance training. Deliberate hydration strategies. Bone density monitoring. Functional goals instead of weight-loss targets. Close follow-up. Awareness of polypharmacy.

The goal for an older adult on a GLP-1 isn’t to lose the most weight possible. It’s to gain the most function, the most independence, and the most years of quality life. When the treatment plan is built around those goals — with the risks managed as carefully as the benefits are pursued — these medications have a real place in the toolkit.

If you’re considering a GLP-1 or already taking one, make sure your provider is thinking about all of this — not just the weight and the A1C, but the muscle, the bones, the balance, and the life you want to be living. That’s a bigger conversation, and it’s a more important one.

---